OS Therapies Incorporated
AMEX:OSTXBiotechnology
Healthcare
$1.15 +5.81%
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
52W Low $1.15High $2.57
Volume 0.50M
Average 0.71M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$14.24B
FY 2025 · Annual
Investing Cash Flow
-$466.42M
FY 2025 · Annual
Financing Cash Flow
$9.44B
FY 2025 · Annual
+73793.9% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75B) |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 268.3K | 4.27B |
| Change in Working Capital | 574.67K | 947.33K | 2.02M | (129.64K) | 9.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 856.48K | 216.43K | 1.35M | (1.05M) | 8.27M |
| Other Working Capital | (281.81K) | 730.9K | 669.65K | 923.69K | 834.81K |
| Other Non-Cash Items | 2.44M | 1.51M | 2.76M | 1.46M | 9.88B |
| Operating Cash Flow | (4.4M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
| Capital Expenditures | (11.93K) | 0 | 0 | 0 | (466.42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 212.41K | 230.88K | 1.15K | 0 | (465.96M) |
| Investing Cash Flow | 200.47K | 230.88K | 1.15K | 0 | (466.42M) |
| Debt Repayment | 2.95M | 3.82M | 3.16M | 1.5M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 5.23M | 8.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (31.25M) | 0 |
| Other Financing Activities | 100K | (172.02K) | (284.18K) | 31.25M | 9.43B |
| Financing Cash Flow | 3.05M | 3.65M | 2.87M | 12.78M | 9.44B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.15M) | 90.69K | (132.5K) | 5.49M | (5.26B) |
| Free Cash Flow | (4.41M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$28.8B
+ D&A$363.1M
+ Stock-Based Comp$4.3B
+ Deferred Tax$0
+ Working Capital$9.1M
+ Other Non-Cash$9.9B
= Operating Cash Flow-$14.2B
- Capex-$466.4K
= Free Cash Flow-$14.2B
Analysis
FY2025 free cash flow is -$14.2B. FCF conversion is 49.5% of net income. Operating cash flow was -$14.2B, with capex of -$466.4K. The largest bridge item is Other Non-Cash at $9.9B.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
Does OSTX generate free cash flow?
OS Therapies Incorporated (OSTX) generated -$14.24B of free cash flow in fiscal 2025.
How much operating cash flow does OSTX produce?
Operating cash flow was -$14.24B, before capital expenditures of $466,423.00.
Continue the stock analysis
Jump to another research area for this company.